|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Francis, K. E.; Kim, S. I.; Friedlander, M.; Gebski, V.; Ray-Coquard, I.; Clamp, A.; Penson, R. T.; Oza, A.; Perri, T.; Huzarski, T.; Martin-Lorente, C.; Cecere, S. C.; Colombo, N.; Ataseven, B.; Fujiwara, K.; Sonke, G.; Vergote, I.; Pujade-Lauraine, E.; Kim, J.-W. und Lee, C. K.
(2022):
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
In: Annals of Oncology, Bd. 33, Nr. 6: S. 593-601
Wasan, H.; Sharma, R.; Heinemann, V.; Sharma, N.; Taieb, J.; Ricke, J.; Peeters, M.; Findlay, M.; Virdee, P. S.; Love, S.; Moschandreas, J.; Dutton, P.; Gebski, V.; Gray, A. M.; Price, D.; Bower, G.; Montazeri, A.; Gibbs, P. und Hazel, G. van
(2017):
FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis.
In: Annals of Oncology, Bd. 28
Trillsch, F.; Mahner, S.; Hilpert, F.; Davies, L.; García-Martínez, E.; Kristensen, G.; Savarese, A.; Vuylsteke, P.; Los, M.; Zagouri, F.; Gladieff, L.; Sehouli, J.; Lee, C. Khoon; Gebski, V. und Pujade-Lauraine, E.
(2016):
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1733-1739
Lindemann, K.; Kristensen, G.; Mirza, M. R.; Davies, L.; Hilpert, F.; Romero, I.; Ayhan, A.; Burges, A.; Rubio, M. J.; Raspagliesi, F.; Huizing, M.; Creemers, G.-J.; Lykka, M.; Lee, C. K.; Gebski, V. und Pujade-Lauraine, E.
(2016):
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1505-1510
Trillsch, F.; Mahner, S.; Hilpert, F.; Davis, L.; Garcia, E.; Kristensen, G.; Savarese, A.; Vuylsteke, P.; Loos, M.; Zagouri, F.; Gladieff, L.; Sehouli, J.; Lee, C. K.; Gebski, V. und Pujade-Lauraine, E.
(2016):
Prognostic and predictive values of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.
In: Oncology Research and Treatment, Bd. 39: S. 93